Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00678769 · ClinicalTrials.gov registry record · Phase 1
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT00678769: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00678769 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 72 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00678769, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of cixutumumab and temsirolimus in treating patients with locally advanced or metastatic cancer. Monoclonal antibodies, such as cixutumumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cixutumumab together with temsirolimus may kill more cancer cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Temsirolimus
- OTHER Pharmacological Study
- DRUG Cixutumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2008-05 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00678769
The ClinicalTrials.gov registry entry for NCT00678769 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00678769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00678769 about?
NCT00678769 is a clinical study titled "Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer". This phase I trial studies the side effects and best dose of cixutumumab and temsirolimus in treating patients with locally advanced or metastatic cancer. Monoclonal antibodies, such as cixutumumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread....
What is the current status of trial NCT00678769?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2008-05. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00678769?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Temsirolimus (DRUG), Pharmacological Study (OTHER), Cixutumumab (DRUG).
Who is sponsoring clinical trial NCT00678769?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.